Last reviewed · How we verify

SPECT MPI

GE Healthcare · Phase 3 active Small molecule

SPECT MPI is a diagnostic imaging agent that uses technetium-99m labeled tracers to visualize myocardial perfusion and detect areas of reduced blood flow in the heart.

SPECT MPI is a diagnostic imaging agent that uses technetium-99m labeled tracers to visualize myocardial perfusion and detect areas of reduced blood flow in the heart. Used for Detection of coronary artery disease and myocardial ischemia, Assessment of myocardial viability post-infarction, Risk stratification in patients with known or suspected coronary artery disease.

At a glance

Generic nameSPECT MPI
SponsorGE Healthcare
Drug classDiagnostic radiopharmaceutical
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

SPECT (Single Photon Emission Computed Tomography) MPI (Myocardial Perfusion Imaging) employs gamma-emitting radiopharmaceuticals that accumulate in viable myocardial tissue proportional to regional blood flow. The imaging allows detection of ischemia, infarction, and viability assessment by comparing perfusion patterns at rest and during stress (exercise or pharmacologic).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: